绝经激素治疗与癌症风险:风险被高估了吗?
该研究基于瑞典全国人群队列,纳入2005年7月至2012年12月期间使用全身性绝经激素治疗(MHT)的290186名40岁以上女性,比较其与瑞典女性背景人群的癌症风险。结果显示,任一MHT的总体癌症标准化发病比(SIR)为1.09(95%CI 1.07-1.11),雌激素单药MHT为1.04(95%CI 1.01-1.06),雌孕激素联合MHT为1.14(95%CI 1.12-1.17);生殖系统癌症风险升高与胃肠道癌症风险降低几乎相抵。
要点
- 任一MHT总体癌症风险轻度升高,SIR=1.09(95%CI 1.07-1.11)。
- 雌孕激素联合MHT风险高于雌激素单药,SIR分别为1.14和1.04。
- 胃肠道癌症风险降低,SIR=0.90(95%CI 0.86-0.94)。
核心结论
- MHT尤其是雌孕激素联合MHT与总体癌症风险轻度升高相关,生殖系统癌症风险升高几乎被胃肠道癌症风险降低所抵消。
研究设计与样本
- 瑞典全国性基于人群的队列研究,纳入2005年7月至2012年12月期间使用全身性MHT的290186名40岁以上女性,与瑞典女性背景人群比较。
主要发现
- 任一MHT的总体癌症SIR为1.09(95%CI 1.07-1.11),雌激素单药MHT为1.04(95%CI 1.01-1.06),雌孕激素联合MHT为1.14(95%CI 1.12-1.17)。
- 雌孕激素联合MHT在70岁以上使用者中SIR最高,为1.33(95%CI 1.26-1.40)。
- 任一MHT使用者侵袭性乳腺癌、子宫内膜癌或卵巢癌合并风险升高,SIR=1.31(95%CI 1.28-1.34)。
- 胃肠道癌症合并风险降低,SIR=0.90(95%CI 0.86-0.94),其中食管癌SIR=0.81(95%CI 0.64-1.00),肝癌SIR=0.81(95%CI 0.65-0.99),结肠癌SIR=0.90(95%CI 0.84-0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We aimed to assess the overall cancer risk among contemporary menopausal hormone therapy (MHT) users in Sweden and the risk for different cancer types. METHODS: A nationwide Swedish population-based cohort study including all 290,186 women aged ≥ 40 years having used systemic MHT during the study period (July 2005 and December 2012), compared with the Swedish female background population. MHT ever-use (all MHT, oestrogen-only MHT [E-MHT] and oestrogen plus progestin MHT [EP-MHT]) was based on the nationwide Prescribed Drug Registry. Cancer diagnoses were grouped into 16 different anatomical locations, for which standardised incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated. RESULTS: The SIR of any cancer was 1.09 (95% CI: 1.07-1.11) following ever MHT, 1.04 (95% CI: 1.01-1.06) for E-MHT and 1.14 (95% CI: 1.12-1.17) for EP-MHT. The highest SIR was found for EP-MHT among users aged ≥70 years (SIR = 1.33, 95% CI: 1.26-1.40). The risk for invasive breast, endometrial or ovarian cancer combined was increased for any MHT (SIR = 1.31, 95% CI: 1.28-1.34). The risk of invasive breast cancer was increased following MHT and increased with age for EP-MHT users. The risk of gastrointestinal cancers combined was decreased (SIR = 0.90, 95% CI: 0.86-0.94), particularly the oesophagus (SIR = 0.81, 95% CI: 0.64-1.00), liver (SIR = 0.81, 95% CI: 0.65-0.99) and colon (SIR = 0.90, 95% CI: 0.84-0.95). CONCLUSIONS: MHT, notably EP-MHT, was associated with a limited increase in overall cancer risk. The increased risk of female reproductive organ cancers was almost balanced by a decreased risk of gastrointestinal cancers.
引用
- Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur J Cancer. 2017. PMID: 28783542. doi:10.1016/j.ejca.2017.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。